DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Mavyret is a drug marketed by Abbvie Inc and is included in two NDAs. There are seven patents protecting this drug.
This drug has four hundred and fifty-four patent family members in forty-four countries.
The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
Mavyret was eligible for patent challenges on August 3, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for MAVYRET
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MAVYRET
Identify potential brand extensions & 505(b)(2) entrants
|NYU Langone Health||Early Phase 1|
|Mayo Clinic||Phase 4|
Pharmacology for MAVYRET
|Country||Patent Number||Estimated Expiration|
|Hong Kong||1223817||⤷ Try it Free|
|Cyprus||1117188||⤷ Try it Free|
|Eurasian Patent Organization||024538||⤷ Try it Free|
|Japan||5906253||⤷ Try it Free|
|South Africa||201903284||⤷ Try it Free|
|European Patent Office||2627651||⤷ Try it Free|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2692346||PA2017033,C2692346||Lithuania||⤷ Try it Free||PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726|
|2692346||2017/046||Ireland||⤷ Try it Free||PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726|
|2368890||300731||Netherlands||⤷ Try it Free||PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119|
|2618831||17C1039||France||⤷ Try it Free||PRODUCT NAME: GLECAPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN ESTER DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728|
|2368890||15C0016||France||⤷ Try it Free||PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119|
|2618831||LUC00037||Luxembourg||⤷ Try it Free||PRODUCT NAME: GLECAPREVIR OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|